Articles From: Endocyte Announces DSMB Recommendation for Continuation of Vintafolide/Docetaxel Combination and Docetaxel Monotherapy Arms of the Phase 2b TARGET Trial in Non-Small Cell Lung Cancer to Endologix to Host Investor Meeting on Wednesday, November 20, 2013


2013/10/11
- DSMB Recommendations Following Interim Futility Analysis  -  - DSMB Recommends an Amendment to Informed Consent Given that the Vintafolide Monotherapy Arm is Unlikely to be Declared Superior to Docetaxel, Patients have Option to Continue Vintafolide Monotherapy - -  Top-Line Results for TARGET Trial Expected in Early 2014 - WEST LAFAYETTE, Ind., Oct.
Sign-up for Endocyte Announces DSMB Recommendation for Continuation of Vintafolide/Docetaxel Combination and Docetaxel Monotherapy Arms of the Phase 2b TARGET Trial in Non-Small Cell Lung Cancer investment picks
2014/2/17
WEST LAFAYETTE, Ind., Feb.
Sign-up for Endocyte Announces Fourth Quarter and Full Year 2013 Earnings Conference Call investment picks
2014/3/21
WEST LAFAYETTE, Ind., March 21, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) today announced results from the Phase 2b TARGET trial, which showed that the study met the primary endpoint for the combination of vintafolide (EC145/MK-8109) and docetaxel in folate receptor (FR)-positive recurrent non-small cell lung cancer (NSCLC) patients.
Sign-up for Endocyte Announces Phase 2b TARGET Trial Results Evaluating Vintafolide/Docetaxel Combination in Non-Small Cell Lung Cancer (NSCLC) Met the Primary Endpoint of Improved Progression Free Survival investment picks
2014/4/4
WEST LAFAYETTE, Ind., April 4, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that three posters will be presented by Endocyte scientists at the 2014 Annual Meeting of the American Association for Cancer Research (AACR) to be held in San Diego, April 5-9, 2014.
Sign-up for Endocyte Announces Presentations at AACR Annual Meeting 2014 investment picks
WEST LAFAYETTE, Ind., Sept.
Sign-up for Endocyte Announces Presentations at the 246th American Chemical Society Meeting & Exposition investment picks
2013/7/18
WEST LAFAYETTE, Ind., July 18, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) , a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that the company will host a conference call on Thursday, Aug.
Sign-up for Endocyte Announces Second Quarter 2013 Earnings Conference Call investment picks
2013/10/23
WEST LAFAYETTE, Ind., Oct.
Sign-up for Endocyte Announces Third Quarter 2013 Earnings Conference Call investment picks
2014/1/24
WEST LAFAYETTE, Ind., Jan.
Sign-up for Endocyte Provides Update on CHMP Review of Pending EU Conditional Marketing Authorization Applications for Vintafolide and Etarfolatide investment picks
2014/2/24
– Committee for Medicinal Products for Human Use ( CHMP) Opinion on Pending EU Marketing Authorization Applications for Vintafolide and Etarfolatide Expected in March Followed by Potential EU Launch – – Key Data Readouts from TARGET Phase 2b Non-Small Cell Lung Cancer (NSCLC) Trial and PROCEED Phase 3 Trial in Platinum-Resistant Ovarian Cancer (PROC) in 1H 2014 – – Launch of Clinical Trials in Solid Tumors, Prostate Cancer and Inflammation with Expanding SMDC Pipeline – – Conference call today at 8:30 a.m. EST – WEST LAFAYETTE, Ind., Feb.
Sign-up for Endocyte Reports Fourth Quarter and Year End 2013 Financial Results and Provides Business Update investment picks
2013/8/1
- Company Completes Enrollment in Phase 2b TARGET Trial in Non-Small Cell Lung Cancer Ahead of Schedule - WEST LAFAYETTE, Ind., Aug.
Sign-up for Endocyte Reports Second Quarter 2013 Financial Results and Provides Business Update investment picks
WEST LAFAYETTE, Ind., Nov.
Sign-up for Endocyte Reports Third Quarter 2013 Financial Results and Provides Business Update investment picks
WEST LAFAYETTE, Ind., Nov.
Sign-up for Endocyte to Present at the 2013 Credit Suisse Healthcare Conference investment picks
2013/11/26
WEST LAFAYETTE, Ind., Nov.
Sign-up for Endocyte to Present at the Piper Jaffray 25th Annual Health Care Conference investment picks
WEST LAFAYETTE, Ind., Aug.
Sign-up for Endocyte to Present at the Wedbush 2013 Life Sciences Management Access Conference investment picks
2014/2/6
WEST LAFAYETTE, Ind., Feb.
Sign-up for Endocyte to Present at Upcoming Conferences investment picks
2014/2/25
WEST LAFAYETTE, Ind., Feb.
Sign-up for Endocyte to Present at Upcoming Conferences in March investment picks
2013/8/27
WEST LAFAYETTE, Ind., Aug.
Sign-up for Endocyte to Present at Upcoming Conferences in September investment picks
2014/3/25
WEST LAFAYETTE, Ind., March 25, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) announced today that it is offering to sell 4.5 million shares of its common stock in an underwritten public offering.
Sign-up for Endocyte, Inc. Announces Proposed Offering of Common Stock investment picks
2014/4/2
WEST LAFAYETTE, Ind., April 2, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) announced today the closing of its previously announced underwritten public offering of 5,175,000 shares of its common stock at a price to the public of $21.00 per share, which includes the exercise in full by the underwriters of their option to purchase 675,000 additional shares.
Sign-up for Endocyte, Inc. Closes Public Offering of Common Stock investment picks
2014/3/27
WEST LAFAYETTE, Ind., March 27, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $21.00 per share.
Sign-up for Endocyte, Inc. Prices Public Offering of Common Stock investment picks
2014/1/21
IRVINE, Calif., Jan.
Sign-up for Endologix Announces Enrollment of First Patient in EVAS FORWARD-IDE Clinical Trial investment picks
IRVINE, Calif., Dec.
Sign-up for Endologix Announces Offering of $75 Million of Convertible Notes investment picks
IRVINE, Calif., Dec.
Sign-up for Endologix Announces Pricing of $75 Million of Convertible Notes investment picks
2014/2/10
IRVINE, Calif., Feb.
Sign-up for Endologix Announces US Launch of the VELA(TM) Proximal Endograft System investment picks
IRVINE, Calif., Dec.
Sign-up for Endologix Receives IDE Approval for the Nellix(R) EndoVascular Aneurysm Sealing System investment picks
2014/2/27
IRVINE, Calif., Feb.
Sign-up for Endologix Reports 25% and 21% Revenue Growth for the Full Year and Fourth Quarter 2013 investment picks
2013/10/30
IRVINE, Calif., Oct.
Sign-up for Endologix Reports 25% Revenue Growth for the Third Quarter 2013 investment picks
2013/7/30
IRVINE, Calif., July 30, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX) , developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and six months ended June 30, 2013.
Sign-up for Endologix Reports 33% Revenue Growth for the Second Quarter 2013 investment picks
2013/11/12
IRVINE, Calif., Nov.
Sign-up for Endologix to Host Investor Meeting on Wednesday, November 20, 2013 investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Endocyte Announces DSMB Recommendation for Continuation of Vintafolide/Docetaxel Combination and Docetaxel Monotherapy Arms of the Phase 2b TARGET Trial in Non-Small Cell Lung Cancer to Endologix to Host Investor Meeting on Wednesday, November 20, 2013
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity